Posted 1 month ago

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung17)

ClinicalTrials.gov ID NCT05215340

Protocol number D763QC00001

Sponsor Astra Zeneca